Login to Your Account



GOOD ‘RESPONSE’

Incyte’s Jakafi strong in top-line phase III polycythemia results

By Randy Osborne
Staff Writer

Friday, March 7, 2014
Incyte Corp. could achieve label expansion with the already successful myelofibrosis (MF) drug Jakafi (ruxolitinib) by the end of this year, thanks to a phase III victory in the myeloproliferative neoplasm known as polycythemia vera (PV), which sometimes advances to MF.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription